Show simple item record

dc.contributor.authorGupta, V
dc.contributor.authorKim, S
dc.contributor.authorHu, Z-H
dc.contributor.authorLiu, Y
dc.contributor.authorAljurf, M
dc.contributor.authorBacher, U
dc.contributor.authorBeitinjaneh, A
dc.contributor.authorCahn, J-Y
dc.contributor.authorCerny, J
dc.contributor.authorCopelan, E
dc.contributor.authorGadalla, SM
dc.contributor.authorGale, RP
dc.contributor.authorGanguly, S
dc.contributor.authorGeorge, B
dc.contributor.authorGerds, AT
dc.contributor.authorGergis, U
dc.contributor.authorHamilton, BK
dc.contributor.authorHashmi, S
dc.contributor.authorHildebrandt, GC
dc.contributor.authorKamble, RT
dc.contributor.authorKindwall-Keller, T
dc.contributor.authorLazarus, HM
dc.contributor.authorLiesveld, JL
dc.contributor.authorLitzow, M
dc.contributor.authorMaziarz, RT
dc.contributor.authorNishihori, T
dc.contributor.authorOlsson, RF
dc.contributor.authorRizzieri, D
dc.contributor.authorSavani, BN
dc.contributor.authorSeo, S
dc.contributor.authorSolh, M
dc.contributor.authorSzer, J
dc.contributor.authorVerdonck, LF
dc.contributor.authorWirk, B
dc.contributor.authorWoolfrey, A
dc.contributor.authorYared, JA
dc.contributor.authorAlyea, EP
dc.contributor.authorPopat, UR
dc.contributor.authorSobecks, RM
dc.contributor.authorScott, BL
dc.contributor.authorNakamura, R
dc.contributor.authorSaber, W
dc.identifierpii: 463999
dc.identifier.citationGupta, V., Kim, S., Hu, Z. -H., Liu, Y., Aljurf, M., Bacher, U., Beitinjaneh, A., Cahn, J. -Y., Cerny, J., Copelan, E., Gadalla, S. M., Gale, R. P., Ganguly, S., George, B., Gerds, A. T., Gergis, U., Hamilton, B. K., Hashmi, S., Hildebrandt, G. C. ,... Saber, W. (2020). Comparison of outcomes of HCT in blast phase of BCR-ABL1(-) MPN with de novo AML and with AML following MDS. BLOOD ADVANCES, 4 (19), pp.4748-4757.
dc.description.abstractComparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.
dc.titleComparison of outcomes of HCT in blast phase of BCR-ABL1(-) MPN with de novo AML and with AML following MDS
dc.typeJournal Article
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleBlood Advances
melbourne.openaccess.statusPublished version
melbourne.contributor.authorSzer, Jeffrey
melbourne.accessrightsAccess this item via the Open Access location

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record